[96a5a0]: / output / allTrials / identified / NCT06672120_identified.json

Download this file

227 lines (227 with data), 9.4 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
{
"info": {
"nct_id": "NCT06672120",
"official_title": "Exercise in Regional Breast Cancer With Neoadjuvant Anthracycline- Based Chemotherapy and Immunotherapy With Checkpoint-Inhibition",
"inclusion_criteria": "* Female patients with newly diagnosed, local triple-negative breast cancer (stage I-III) ≥ 18 to 50 years of age scheduled for immunochemotherapy with pembrolizumab and anthracycline-based chemotherapy\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 50 Years",
"exclusion_criteria": "* Unstable cardiac condition (clinical suspicion of progress or unstable coronary artery disease, signs of acute heart failure, haemodynamically relevant arrhythmias)\n* Orthopaedic disability to exercise",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Female patients with newly diagnosed, local triple-negative breast cancer (stage I-III) ≥ 18 to 50 years of age scheduled for immunochemotherapy with pembrolizumab and anthracycline-based chemotherapy",
"criterions": [
{
"exact_snippets": "Female patients",
"criterion": "gender",
"requirements": [
{
"requirement_type": "value",
"expected_value": "female"
}
]
},
{
"exact_snippets": "newly diagnosed, local triple-negative breast cancer",
"criterion": "breast cancer type",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "newly diagnosed"
},
{
"requirement_type": "locality",
"expected_value": "local"
},
{
"requirement_type": "subtype",
"expected_value": "triple-negative"
}
]
},
{
"exact_snippets": "stage I-III",
"criterion": "cancer stage",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1,
"unit": "stage"
},
{
"operator": "<=",
"value": 3,
"unit": "stage"
}
]
}
}
]
},
{
"exact_snippets": "≥ 18 to 50 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 18,
"unit": "years"
},
{
"operator": "<=",
"value": 50,
"unit": "years"
}
]
}
}
]
},
{
"exact_snippets": "scheduled for immunochemotherapy with pembrolizumab and anthracycline-based chemotherapy",
"criterion": "treatment plan",
"requirements": [
{
"requirement_type": "scheduled",
"expected_value": [
"immunochemotherapy with pembrolizumab",
"anthracycline-based chemotherapy"
]
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 50 Years",
"criterions": [
{
"exact_snippets": "maximum age of 50 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 50,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Unstable cardiac condition (clinical suspicion of progress or unstable coronary artery disease, signs of acute heart failure, haemodynamically relevant arrhythmias)",
"criterions": [
{
"exact_snippets": "Unstable cardiac condition (clinical suspicion of progress or unstable coronary artery disease",
"criterion": "unstable coronary artery disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Unstable cardiac condition ... signs of acute heart failure",
"criterion": "acute heart failure",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Unstable cardiac condition ... haemodynamically relevant arrhythmias",
"criterion": "haemodynamically relevant arrhythmias",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Orthopaedic disability to exercise",
"criterions": [
{
"exact_snippets": "Orthopaedic disability to exercise",
"criterion": "orthopaedic disability",
"requirements": [
{
"requirement_type": "impact on exercise",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}